AdAlta

Home

Announcements

Why Invest

Updates

Webinars

Lora

Why Goldman Sachs says now is the time to buy into China's biotech future

upload.jpg

Ziyi Chen, Head of Asia Healthcare Research at Goldman Sachs discusses the rise of China biotech, highlighting why it is such a rich and valuable pool of innovation for AdAlta's "East to West" cellular immunotherapy strategy.

He notes "Chinese biotech has become an emerging source of innovation globally ... 50% of drug candidates entering clinical trials in the first half of 2025 were from China".

China policy settings over the past decade

Oncology and immunology (key for cellular immunotherapies) and obesity are leading the way